TY - JOUR
T1 - Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART
AU - Süveg, Krisztian
AU - Pechoux, Cecile Le
AU - Faivre-Finn, Corinne
AU - Putora, Paul M.
AU - Ruysscher, Dirk De
AU - Widder, Joachim
AU - Houtte, Paul Van
AU - Troost, Esther G.C.
AU - Slotman, Ben J.
AU - Ramella, Sara
AU - Pöttgen, Christoph
AU - Peeters, Stephanie T.H.
AU - Nestle, Ursula
AU - McDonald, Fiona
AU - Dziadziuszko, Rafal
AU - Belderbos, José
AU - Ricardi, Umberto
AU - Manapov, Farkhad
AU - Lievens, Yolande
AU - Geets, Xavier
AU - Dieckmann, Karin
AU - Guckenberger, Matthias
AU - Andratschke, Nicolaus
AU - Glatzer, Markus
N1 - Funding Information:
Prof Corinne Faivre-Finn was supported by a grant from the NIHR Manchester Biomedical Research Centre.
Funding Information:
B.J. Slotman – research funding from Varian medical systems and ViewRay Inc.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Background: The role of postoperative radiation therapy (PORT) in stage III N2 NSCLC is controversial. We analyzed decision-making for PORT among European radiation oncology experts in lung cancer. Methods: Twenty-two experts were asked before and after presentation of the results of the LungART trial to describe their decision criteria for PORT in the management of pN+ NSCLC patients. Treatment strategies were subsequently converted into decision trees and analyzed. Results: Following decision criteria were identified: extracapsular nodal extension, incomplete lymph node resection, multistation lymph nodes, high nodal tumor load, poor response to induction chemotherapy, ineligibility to receive adjuvant chemotherapy, performance status, resection margin, lung function and cardiopulmonary comorbidities. The LungART results had impact on decision-making and reduced the number of recommendations for PORT. The only clear indication for PORT was a R1/2 resection. Six experts out of ten who initially recommended PORT for all R0 resected pN2 patients no longer used PORT routinely for these patients, while four still recommended PORT for all patients with pN2. Fourteen experts used PORT only for patients with risk factors, compared to eleven before the presentation of the LungART trial. Four experts stated that PORT was never recommended in R0 resected pN2 patients regardless of risk factors. Conclusion: After presentation of the LungART trial results at ESMO 2020, 82% of our experts still used PORT for stage III pN2 NSCLC patients with risk factors. The recommendation for PORT decreased, especially for patients without risk factors. Cardiopulmonary comorbidities became more relevant in the decision-making for PORT.
AB - Background: The role of postoperative radiation therapy (PORT) in stage III N2 NSCLC is controversial. We analyzed decision-making for PORT among European radiation oncology experts in lung cancer. Methods: Twenty-two experts were asked before and after presentation of the results of the LungART trial to describe their decision criteria for PORT in the management of pN+ NSCLC patients. Treatment strategies were subsequently converted into decision trees and analyzed. Results: Following decision criteria were identified: extracapsular nodal extension, incomplete lymph node resection, multistation lymph nodes, high nodal tumor load, poor response to induction chemotherapy, ineligibility to receive adjuvant chemotherapy, performance status, resection margin, lung function and cardiopulmonary comorbidities. The LungART results had impact on decision-making and reduced the number of recommendations for PORT. The only clear indication for PORT was a R1/2 resection. Six experts out of ten who initially recommended PORT for all R0 resected pN2 patients no longer used PORT routinely for these patients, while four still recommended PORT for all patients with pN2. Fourteen experts used PORT only for patients with risk factors, compared to eleven before the presentation of the LungART trial. Four experts stated that PORT was never recommended in R0 resected pN2 patients regardless of risk factors. Conclusion: After presentation of the LungART trial results at ESMO 2020, 82% of our experts still used PORT for stage III pN2 NSCLC patients with risk factors. The recommendation for PORT decreased, especially for patients without risk factors. Cardiopulmonary comorbidities became more relevant in the decision-making for PORT.
KW - Adjuvant
KW - Decision tree
KW - Decision-making
KW - NSCLC
KW - Radiotherapy
U2 - 10.1016/j.cllc.2021.08.007
DO - 10.1016/j.cllc.2021.08.007
M3 - Article
SN - 1525-7304
VL - 22
SP - 579
EP - 586
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 6
ER -